Article Sidebar
Published:
Feb 5, 2023Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Co-administration of indacaterol and tiotropium bromide for the treatment of chronic obstructive pulmonary disease and bronchiectasis, and effect on IL-8 and CRP levels
Abstract
Purpose: To investigate the efficacy of indacaterol plus tiotropium bromide in chronic obstructive pulmonary disease (COPD) complicated by bronchiectasis and the impact on IL-8 and C reactive protein (CRP) levels.
Methods: Sixty enrolled patients with COPD and bronchiectasis who received treatment in Yantai Qishan Hospital, Yuyan, China from June 2017 to December 2019 were randomly allocated to group A (n = 30) and group B (n = 30). Group A received inhalation of indacaterol plus tiotropium bromide. Group B received only tiotropium bromide inhalation therapy. Therapeutic effects and appropriate serum indicators were compared.
Results: Maximal mid-expiratory flow (MMF), maximal voluntary ventilation (MVV), and forced expiratory volume in one second (FEV1.0) levels of the patients were significantly elevated, and group A showed a significantly higher values than group B (p < 0.05). The serum levels of IL-8, CRP, and serum calcitonin (PCT) in both groups were lower than before treatment, but the decrease in group A was significantly greater than that in group B (p < 0.05). The SaO2, PaO2, and PaO2/FiO2 levels in both groups increased, but the increase in group A was higher than that in group B (p < 0.05). Group A showed a significantly lower total incidence of complications than group B (p < 0.05).
Conclusion: Indacaterol plus tiotropium bromide produced significant effects in the treatment of COPD with bronchiectasis, which ameliorate lung function and inflammation status in the body and therefore have the potential of being utilized in clinical practice.
